Zimam Mahmud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11040608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FOXA1 is a determinant of drug resistance in breast cancer cells. Breast Cancer Research and Treatment, 2021, 186, 317-326.	2.5	12
2	Reciprocal regulation between GCN2 (elF2AK4) and PERK (elF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival. Molecular and Cellular Endocrinology, 2020, 515, 110932.	3.2	9
3	Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells. Oncogene, 2019, 38, 6382-6398.	5.9	28
4	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer. Cancers, 2019, 11, 1067.	3.7	29
5	Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases. Biochemical Pharmacology, 2019, 163, 391-403.	4.4	5
6	Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation. BMC Cancer, 2019, 19, 1106.	2.6	13
7	Characterization of FOXO Acetylation. Methods in Molecular Biology, 2019, 1890, 77-90.	0.9	4
8	Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis. Molecular and Cellular Endocrinology, 2018, 462, 82-92.	3.2	22
9	Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket. Journal of Medicinal Chemistry, 2017, 60, 1928-1945.	6.4	49